Literature DB >> 32583169

COVID-19-related strokes in adults below 55 years of age: a case series.

Farzad Ashrafi1, Alireza Zali2, Davood Ommi2, Mehri Salari2, Alireza Fatemi2, Mehran Arab-Ahmadi3, Behdad Behnam4, Arash Azhideh2, Mohammad Vahidi2, Maryam Yousefi-Asl2, Reza Jalili Khoshnood2, Soroor Advani2.   

Abstract

BACKGROUND: Coronavirus infection is a novel respiratory disease affecting people across the world. Although the majority of patients present with fever, dyspnea, cough, or myalgia, various signs and symptoms have been reported for this disease. Recently, neurological symptoms have been noticed in patients with COVID-19 with unknown etiology. However, the occurrence of strokes in young and middle aged patients with COVID-19 is not fully explained.
METHODS: In this series, six patients younger than 55 years of age with diagnosis of stroke and a confirmed diagnosis of COVID-19 were evaluated for symptoms, lab data, imaging findings, and outcomes from March 2020 to the end of April 2020 from all stroke cases in a tertiary academic hospital. Patients older than 55 and all others who had evidence of cardiac abnormalities (arrhythmia/valvular) were excluded.
RESULTS: Fever, myalgia, cough, and dyspnea were the most common clinical symptoms noted in 66.66% (4/6), 66.66% (4/6), 50% (3/6), and 50% (3/6) of the patients, respectively. The mean ± standard deviation (SD) of National Institutes of Health Stroke Scale (NIHSS) for the patient was 10.16 ± 7.13 (ranged 5-24). The most involved area was middle cerebral artery (MCA) (five in MCA versus one in basal ganglia) and the majority of our patients had a low lung involvement score (mean ± SD: 13.16 ± 6.49 out of 24). Finally, one patient was deceased and rest discharged.
CONCLUSION: Stroke may be unrelated to age and the extent of lung involvement. However, different factors may play roles in co-occurrence of stroke and COVID-19 and its outcome. Future studies with long-term follow-up and more cases are needed to assess prognostic factors.

Entities:  

Keywords:  COVID-19; Coronavirus; Neurological manifestation; Stroke

Mesh:

Year:  2020        PMID: 32583169      PMCID: PMC7311861          DOI: 10.1007/s10072-020-04521-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


Background

Coronavirus infection is a novel, highly contagious respiratory disease caused by SARS-CoV-2 affecting people across the world [1]. The most frequent symptoms are fever, dyspnea, cough, or myalgia [2]. Although various signs and symptoms have been reported for this disease, some of them are not clear yet. It may involve both the central nervous system (CNS) and peripheral nervous system (PNS). In this regard, headache, vertigo, cognitive impairment, epilepsy, acute cerebrovascular event ataxia, ageusia, anosmia, neuralgia, and Guillain-Barre syndrome are some of the reported neurological manifestations [3-5]. According to previous reports, viral infections including COVID-19 may play a role as a potential risk factor in developing cerebrovascular diseases such as acute ischemic stroke especially in patients with the severe form of infection [6]. The role of COVID-19 in initiating proinflammatory and hypercoagulable state has been well described [7]. Also, because of inflammation, hypoxia, immobilization, and diffuse intravascular coagulation (DIC), patients with COVID-19 are at a higher risk of both venous and arterial thromboembolic events. Recently, heparin has been associated with lower mortality in severe cases of COVID-19 or with elevated D-dimer [8]. However, the mechanism and its pathology are rarely understood. There are currently limited data about patient’s characteristics, extent of lung involvement, and other factors in the patients with stroke and COVID-19. This series is presented to point out to physicians to keep cerebrovascular attacks in mind as an important condition in patients with COVID-19 that may need urgent interventions. In addition, the other aim of this study was to show coronavirus as a causative agent for stroke which is unrelated to age and lung involvement extension.

Cases

Our cases were patients presented to our academic tertiary hospital, stroke unit, with clinical symptoms of stroke from March 2020 to the end of April 2020. We exclude patients older than 55 and all others who had evidence of cardiac arrhythmia or cardiac valvular disease based on electrocardiogram, transthoracic and transesophageal echocardiography, and 24-h Holter monitoring findings. Although all patients primarily presented with neurological symptoms, the diagnosis of COVID-19 was made based on positive nasopharyngeal polymerase chain reaction (PCR) and lung CT scan except one of them who was a 49-year-old female with previous diagnosis of COVID-19 who was discharged from another hospital and admitted to our stroke unit 5 days later. The mean age (±standard deviation [SD]) was 43.5 ± 7.42 (range 33–53 years) and half of them were male. COVID-19 symptoms were evaluated by history taking except one of our cases (33 years old female) who presented altered levels of consciousness and fever. The most common sign and symptom of COVID-19 were fever (four/six), myalgia (four/six), cough (three/six), and dyspnea (three/six). All patients had O2 saturation below 92% in room air while none of them were hypotensive. Half of the patients had history of hypertension and one case had diabetes mellitus. Mean (±standard deviation) of National Institutes of Health Stroke Scale (NIHSS) for the patient was 10.16 ± 7.13 (ranged 5–24). Detailed clinical features and outcomes of the patients are noted in Table 1. In addition, the initial laboratory findings are shown in Table 2.
Table 1

Demographic, clinical features, and outcome of the patients

Patient No.Age, year/genderComorbiditiesFeverCOVID-19 symptomsStroke symptomsO2 sat on room air (%)NIHSSHospital length of stayOutcome
133/F+lethargyReduced level of consciousness, global aphasia, right side hemiplegia85245Death
239/M+Cough, headache, myalgia, dyspneaLeft side hemiparesis, homonymous hemianopia, sensory deficit, dysarthria89910Discharged
349/FHTNMyalgiaLeft side hemiplagia,heminimous hemianopia, dysarthera901114Discharged
440/MMyalgia, dyspneaRight side hemiparesis, dysarthera8967Discharged
553/MHTN+Cough, diarrheaLeft side hemiparesis, dysarthria9157Discharged
647/ FDM/HTN+Myalgia, cough and dyspneaRight side hemiparesis, dysarthria8269Discharged

F female, M male, HTN hypertension, NIHHS National Institutes of Health Stroke Scale

Table 2

Summary of baseline laboratory findings

123456Summery (mean ± SD)
White blood cell count8000550087007400450090007183.33 ± 1808.22
Neutrophil count5600470069606364292576505699.83 ± 1705.38
Lymphocyte count24008001392888157513501400.83 ± 575.38
Hemoglobin (mg/dL)9.810.711.816.815.812.512.89 ± 2.80
Platelet × 103305183146223101210194.66 ± 69.98
CRP (mg/L)2412275121015.0 ± 8.57
LDH (μ/L)3453471393356430460555.16 ± 413.24
Cr (mg/dL)0.80.81.091.21.21.041.02 ± 0.18
AST (μ/L)16149421171128.83 ± 32.09
ALT (μ/L)151110613101428.16 ± 38.17
ALP (μ/L)143134415209204162211.16 ± 104.52
Albumin (g/dL)5.014.83.94.84.14.34.48 ± 0.44
D-Dimer7288109546826001293844.50 ± 250.63
PT (s)13131314131413.33 ± 0.51
PTT (s)28403040383034.33 ± 5.57
INR1111.111.11.03 ± 0.51

CRP C-reactive protein, LDH lactic acid dehydrogenase, Cr creatinine, BUN blood urea nitrogen, AST aspartate transaminase, ALT alanine transaminase, ALP alkaline phosphatase, PT prothrombin time, PTT partial thromboplastin time, INR international normalized ratio

Demographic, clinical features, and outcome of the patients F female, M male, HTN hypertension, NIHHS National Institutes of Health Stroke Scale Summary of baseline laboratory findings CRP C-reactive protein, LDH lactic acid dehydrogenase, Cr creatinine, BUN blood urea nitrogen, AST aspartate transaminase, ALT alanine transaminase, ALP alkaline phosphatase, PT prothrombin time, PTT partial thromboplastin time, INR international normalized ratio All patients underwent imaging studies for stroke and also chest CT scan with low-dose protocol [9]. The initial chest CT scan evaluated for estimation of lung involvement score using zonal involvement percentage method with the maximum score of 24 [10]. The mean score (±SD) was 13.16 ± 6.49 (ranged 2–16) and bilateral ground glass opacities were the most predominant pattern (Fig. 2).
Fig. 2

Thirty-nine-year-old male with fever, cough, and mylgia from 6 days before presentation and sudden onset of left side hemiplegia and dysartheria. a Hypodensities in right MCA branch territorty suggestive of subacute infarct. b Diffused ground glass opacities with interalobular septal thickening in superior segment of left lung lower lobes highly suggestive for COVID-19

Brain CT scan findings revealed the stroke territories as follows: right middle cerebral artery (MCA) infarction (n = 3), left MCA (n = 2), and left basal ganglia infarction (n = 1), and the majority of the patients had large vessel stroke. Figures 1, 2, and 3 show brain CT beside lung CT scans of three patients. Our data demonstrated that the majority of our patients had low lung involvement rate while they had more severe conditions based on NIHSS score. Carotid duplex was negative for any significant findings (stenosis, atherosclerotic plaque, or dissection) and results of transcranial color-coded duplex ultrasonography (TCCS) have been summarized in Table 3.
Fig. 1

Thirty-three-year-old female with fever and reduced level of consciuosness who had a history of exposure to known case of COVID-19 in his family. a Left MCA territory hypodencities in brain CT scan (a) and increased signal of cortex, white matter, head of left caudete, lentiform nulclei, and anterior horn of internal capsule in T2 and FLAIR brain MRI sequences (c, d), in favor of subacute infarct. b Small subpleuroal consodiation in superior segment of right lung inferior lobe highly suggestive for COVID-19

Fig. 3

Forty-nine-year-old female with pervious history of moderate COVID-19 who admitted to our stroke unit with left side hemiplegia, sensory deficiet, and dysarthria. a Wedge-shaped hypodensities in right MCA territory consistent with subacute infarct in brain CT scan. b Diffused peripheral and central consoliadtion patches with crazy paving pattern in some areas consistent with late phase of COVID-19

Table 3

Summary of baseline imaging findings

Patient No.Infarcted area based on imagingLung CT scan findings (lung involvement score out of 24)TCCS
1Left middle cerebral artery territorySmall subpleuroal consodiation in right lower lobes (2)Flow was not detected in Left MCA.
2Right middle cerebral artery territoryGround glass opacities in left lower lobes (3)Poor temporal window
3Right middle cerebral artery territoryDiffused consoliadtion patches (16)Normal
4Left middle cerebral artery territoryBilateral peripheral ground glass opacities in lower zones (4)Normal
5Right middle cerebral artery territoryBilateral peripheral ground glass opacities in middle zones (8)Normal
6Left basal gangliaRight side lower and middle zones ground glass with sub pleural ground glass opacities in left lower zone (10)Poor temporal window

TCCS transcranial color-coded duplex ultrasonography, MCA middle cerebral artery

Thirty-three-year-old female with fever and reduced level of consciuosness who had a history of exposure to known case of COVID-19 in his family. a Left MCA territory hypodencities in brain CT scan (a) and increased signal of cortex, white matter, head of left caudete, lentiform nulclei, and anterior horn of internal capsule in T2 and FLAIR brain MRI sequences (c, d), in favor of subacute infarct. b Small subpleuroal consodiation in superior segment of right lung inferior lobe highly suggestive for COVID-19 Thirty-nine-year-old male with fever, cough, and mylgia from 6 days before presentation and sudden onset of left side hemiplegia and dysartheria. a Hypodensities in right MCA branch territorty suggestive of subacute infarct. b Diffused ground glass opacities with interalobular septal thickening in superior segment of left lung lower lobes highly suggestive for COVID-19 Forty-nine-year-old female with pervious history of moderate COVID-19 who admitted to our stroke unit with left side hemiplegia, sensory deficiet, and dysarthria. a Wedge-shaped hypodensities in right MCA territory consistent with subacute infarct in brain CT scan. b Diffused peripheral and central consoliadtion patches with crazy paving pattern in some areas consistent with late phase of COVID-19 Summary of baseline imaging findings TCCS transcranial color-coded duplex ultrasonography, MCA middle cerebral artery Regarding our national guidelines, all patients were placed on hydroxychloroquine 400 mg stat and lopinavir/ritonavir 400/100 mg twice daily and intravenous antibiotic. In addition, because all the patients were presented to the emergency room 3 h after their symptom initiation, they were not candidate for thrombolytic therapy so all of them underwent medical treatment with ASA and Plavix for secondary prevention. All patients were followed up to the study endpoint, five patients were discharged; however, one case did not survive.

Discussion

This series showed the co-occurrence of stroke and COVID-19 in adults younger than 55 years of age. To date, there is limited data on the association of COVID-19 and ischemic stroke mechanism, clinical course, prevention, management, and risk stratification. Valderrama et al. reported a 52-year-old man with COVID-19 who presented with sudden onset hemiparesis and aphasia (NIHSS: 20) on his seventh day of treatment and brain CT scan confirmed the diagnosis of stroke in MCA territory. On further work up, they did not find any risk factor for stroke [11]. In this study, the majority of our patients (five/six) were not known cases of COVID-19 infection and all of them were admitted to our stroke unit with neurological complaints while Mao et al. reported the occurrence of stroke in approximately 2% of COVID-19 patients during their admission [12]. In a study by TJ Oxley et al., large-vessel strokes were presented in five COVID-19 cases younger than 50 years old, and unlike our patients, all of them had severe COVID-19 [13]. Avula et al., described acute stroke in four old-aged patients (range 73–88 years) with confirmed diagnosis of COVID-19, while the oldest patient in this study was 53 years old [14]. It seems that factors such as direct virus invasion, inflammatory processes, cytokine release, hypoxemia, hypotension, or vasculitis are possible mechanisms of coronavirus affecting the nervous system. This is the first study evaluating the association of long involvement extension and stroke severity. In this regard, our cases showed that lung involvement extension may be unrelated to developing a stroke and its severity based on NIHSS. On the other hand, D-Dimer level may play a critical role as a prognostic factor as elevated D-Dimer levels were seen in all of our patients. Poggiali et al. reported two cases of COVID-19 who complicated with DVT and PE after at least 10 days since their symptoms started [15]. Also, based on a recent study, COVID-19 could be predisposed to venous and arterial thromboembolism leading to diffuse intravascular coagulation, severe inflammation, immobilization, and hypoxia [16]. An investigation on ICU-admitted patients with COVID-19 showed that the incidence of thrombotic complications was extremely high (31%). The study revealed that pharmacological thrombosis prophylaxis is critically important to be added to the treatment regimen of all COVID-19 patients admitted to ICU [16].

Conclusion

In conclusion, COVID-19 can cause thrombotic complications, hyper-inflammation, and tissue damage, which may increase the risk of ischemic stroke in young and middle aged patients even in early stages and mild forms of COVID-19.
  14 in total

1.  CT Features of Coronavirus Disease 2019 (COVID-19) Pneumonia in 62 Patients in Wuhan, China.

Authors:  Shuchang Zhou; Yujin Wang; Tingting Zhu; Liming Xia
Journal:  AJR Am J Roentgenol       Date:  2020-03-05       Impact factor: 3.959

2.  Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Ischemic Stroke.

Authors:  Eduard Valdes Valderrama; Kelley Humbert; Aaron Lord; Jennifer Frontera; Shadi Yaghi
Journal:  Stroke       Date:  2020-05-12       Impact factor: 7.914

3.  Prominent changes in blood coagulation of patients with SARS-CoV-2 infection.

Authors:  Huan Han; Lan Yang; Rui Liu; Fang Liu; Kai-Lang Wu; Jie Li; Xing-Hui Liu; Cheng-Liang Zhu
Journal:  Clin Chem Lab Med       Date:  2020-06-25       Impact factor: 3.694

4.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.

Authors:  Ning Tang; Huan Bai; Xing Chen; Jiale Gong; Dengju Li; Ziyong Sun
Journal:  J Thromb Haemost       Date:  2020-04-27       Impact factor: 5.824

5.  Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis.

Authors:  F A Klok; M J H A Kruip; N J M van der Meer; M S Arbous; D Gommers; K M Kant; F H J Kaptein; J van Paassen; M A M Stals; M V Huisman; H Endeman
Journal:  Thromb Res       Date:  2020-04-30       Impact factor: 3.944

6.  COVID-19 presenting as stroke.

Authors:  Akshay Avula; Krishna Nalleballe; Naureen Narula; Steven Sapozhnikov; Vasuki Dandu; Sudhamshi Toom; Allison Glaser; Dany Elsayegh
Journal:  Brain Behav Immun       Date:  2020-04-28       Impact factor: 7.217

7.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

8.  Deep Vein Thrombosis and Pulmonary Embolism: Two Complications of COVID-19 Pneumonia?

Authors:  Erika Poggiali; Davide Bastoni; Eva Ioannilli; Andrea Vercelli; Andrea Magnacavallo
Journal:  Eur J Case Rep Intern Med       Date:  2020-04-08

Review 9.  Nervous system involvement after infection with COVID-19 and other coronaviruses.

Authors:  Yeshun Wu; Xiaolin Xu; Zijun Chen; Jiahao Duan; Kenji Hashimoto; Ling Yang; Cunming Liu; Chun Yang
Journal:  Brain Behav Immun       Date:  2020-03-30       Impact factor: 7.217

Review 10.  Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review.

Authors:  Sasmita Poudel Adhikari; Sha Meng; Yu-Ju Wu; Yu-Ping Mao; Rui-Xue Ye; Qing-Zhi Wang; Chang Sun; Sean Sylvia; Scott Rozelle; Hein Raat; Huan Zhou
Journal:  Infect Dis Poverty       Date:  2020-03-17       Impact factor: 4.520

View more
  18 in total

1.  COVID-19 related strokes: Pandora's Box may open as the p(c)lot thickens!

Authors:  R Magoon
Journal:  Neurologia (Engl Ed)       Date:  2021-03-19

2.  Neurological Manifestations and their Correlated Factors in COVID-19 Patients; a Cross-Sectional Study.

Authors:  Farzad Ashrafi; Davood Ommi; Alireza Zali; Sina Khani; Amirali Soheili; Mehran Arab-Ahmadi; Behdad Behnam; Shabnam Nohesara; Farbod Semnani; Alireza Fatemi; Mehri Salari; Reza Jalili Khoshnood; Mohammad Vahidi; Niloofar Ayoobi-Yazdi; Saeed Hosseini Toudeshki; Elham Sobhrakhshankhah
Journal:  Arch Acad Emerg Med       Date:  2021-04-27

3.  The Association of Cerebrovascular Disease with Adverse Outcomes in COVID-19 Patients: A Meta-Analysis Based on Adjusted Effect Estimates.

Authors:  Jie Xu; Wenwei Xiao; Xuan Liang; Peihua Zhang; Li Shi; Ying Wang; Yadong Wang; Haiyan Yang
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-08-28       Impact factor: 2.136

4.  Impact of COVID-19 on Future Ischemic Stroke Incidence.

Authors:  Aisha Elfasi; Franklin D Echevarria; Robert Rodriguez; Yoram A Roman Casul; Anna Yuzefovich Khanna; Robert T Mankowski; Alexis N Simpkins
Journal:  eNeurologicalSci       Date:  2021-02-01

Review 5.  Severe Neurologic Complications of SARS-CoV-2.

Authors:  Daniella C Sisniega; Alexandra S Reynolds
Journal:  Curr Treat Options Neurol       Date:  2021-03-31       Impact factor: 3.598

6.  COVID-19-Related Acute Ischemic Stroke in Young Adults: What Is the Optimal Antithrombotic Regimen for Secondary Prevention?

Authors:  Fahimeh Vahabizad; Maryam Sharifian Dorche; Pegah Mohammadi; Kasra Khatibi; Ashkan Mowla
Journal:  J Neurol Res       Date:  2020-08-02

Review 7.  COVID-19: Neuroimaging Features of a Pandemic.

Authors:  Theodoros Ladopoulos; Ramin Zand; Shima Shahjouei; Jason J Chang; Jeremias Motte; Jeyanthan Charles James; Aristeidis H Katsanos; Ali Kerro; Ghasem Farahmand; Alaleh Vaghefi Far; Nasrin Rahimian; Seyed Amir Ebrahimzadeh; Vida Abedi; Matilda Papathanasiou; Adnan Labedi; Ruth Schneider; Carsten Lukas; Sotirios Tsiodras; Georgios Tsivgoulis; Christos Krogias
Journal:  J Neuroimaging       Date:  2021-01-09       Impact factor: 2.486

8.  Neuroradiological Features of Mild and Severe SARS-CoV-2 Infection.

Authors:  Simon Pan; Willam C Chen; Joe D Baal; Leo P Sugrue
Journal:  Acad Radiol       Date:  2020-08-29       Impact factor: 3.173

Review 9.  Studying the neuropsychological sequelae of SARS-CoV-2: lessons learned from 35 years of neuroHIV research.

Authors:  Andrew Levine; Ned Sacktor; James T Becker
Journal:  J Neurovirol       Date:  2020-09-03       Impact factor: 2.643

Review 10.  COVID-19 and its impact on neurological manifestations and mental health: the present scenario.

Authors:  Shehnaz Sultana; Venkateshwari Ananthapur
Journal:  Neurol Sci       Date:  2020-08-31       Impact factor: 3.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.